Published in Diabet Med on September 01, 2008
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia (2009) 4.81
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol (2009) 1.33
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21
The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2010) 1.12
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists! Diabetes Care (2013) 1.06
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2009) 0.85
Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine (2014) 0.84
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne) (2013) 0.83
From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res (2011) 0.82
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes Metab Syndr Obes (2010) 0.81
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab (2011) 0.80
Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes. Sci Rep (2015) 0.80
Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr (2013) 0.80
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Sci Rep (2015) 0.79
GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) (2015) 0.78
Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf (2012) 0.76
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul) (2016) 0.76
Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab Syndr Obes (2010) 0.76
Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. J Diabetes Investig (2013) 0.75
Managing insulin resistance: role of liraglutide. Clin Pharmacol (2010) 0.75
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol (2005) 2.92
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med (2008) 2.04
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia (2004) 1.56
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res (2004) 1.37
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia (2009) 4.81
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab (2001) 3.09
The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia (2007) 3.07
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes (2001) 3.06
Insulin resistance in microvascular angina (syndrome X) Lancet (1993) 3.02
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia (2002) 2.97
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 2.41
The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia (2009) 2.25
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab (2009) 2.23
Granulomatous prostatitis. Scand J Urol Nephrol (1973) 2.05
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med (2008) 2.04
[New discoveries about the cause of diabetes. Type 2 diabetes mellitus changed to "obesity-dependent diabetes mellitus"]. Ugeskr Laeger (2001) 2.02
Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes (1997) 2.00
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 1.86
Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia (2005) 1.85
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia (2008) 1.75
Acute pain induces insulin resistance in humans. Anesthesiology (2001) 1.72
High frequency of sub-optimal semen quality in an unselected population of young men. Hum Reprod (2000) 1.69
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest (1991) 1.67
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab (2003) 1.66
Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab (2012) 1.63
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care (1999) 1.62
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract (2008) 1.55
Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis. Acta Physiol (Oxf) (2007) 1.52
Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia (2012) 1.52
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res (2005) 1.45
Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg (2012) 1.42
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
[Evaluation of blood loss and absorption of irrigating fluid in transurethral resection of the prostate]. Ugeskr Laeger (1998) 1.40
Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40
Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. Proc Natl Acad Sci U S A (1995) 1.40
Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab (2001) 1.26
Rupture of fetal membranes and premature delivery associated with group B streptococci in urine of pregnant women. Lancet (1984) 1.26
Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes (2001) 1.25
Clinical observations on the corneal thickness and the corneal endothelium in diabetes mellitus. Br J Ophthalmol (1981) 1.24
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes (2006) 1.23
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia (2013) 1.22
The testes after torsion. Br J Urol (1978) 1.21
Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta (1982) 1.19
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest (1995) 1.17
Glut 4 content in the plasma membrane of rat skeletal muscle: comparative studies of the subcellular fractionation method and the exofacial photolabelling technique using ATB-BMPA. FEBS Lett (1993) 1.15
Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol (1990) 1.15
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab (2012) 1.15
Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab (2000) 1.14
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab (2003) 1.13
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia (2007) 1.13
The effect of intense exercise on postprandial glucose homeostasis in type II diabetic patients. Diabetologia (1999) 1.12
Smoking reduces insulin absorption from subcutaneous tissue. Br Med J (Clin Res Ed) (1982) 1.12
Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia (2009) 1.11
The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept (1984) 1.11
Hypomagnesemia, a risk factor in diabetic retinopathy. Diabetes (1978) 1.11
Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) (2013) 1.10
Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab (1981) 1.08
Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab (2011) 1.08
Relative abundance of denitrifying and dinitrogen-fixing bacteria in layers of a forest soil. FEMS Microbiol Ecol (2001) 1.07
Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab (2003) 1.07
Hormonal, metabolic, and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes (1981) 1.07
Cimetidine for severe gastroduodenal haemorrhage: a randomized controlled trial. Scand J Gastroenterol (1980) 1.07
Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia (1995) 1.07
Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics. Br Med J (1979) 1.07
Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care (1998) 1.06
Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest (1982) 1.05
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care (2001) 1.05
Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J (1979) 1.04
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab (2010) 1.04
Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am J Physiol (1994) 1.04
Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab (1983) 1.03
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes. Diabetologia (2011) 1.03
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther (2009) 1.02
Depressed suppressor cell activity in patients with newly diagnosed insulin-dependent diabetes mellitus. Clin Exp Immunol (1980) 1.02
Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab (2014) 1.02
GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia (1996) 1.02
Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia (1981) 1.01
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism (1999) 1.01